Wave Life Sciences .(US:WVE) Jin Rong Jie·2025-12-09 14:52Core Viewpoint - Wave Life Sciences' obesity candidate drug WVE-007 shows promising results in its Phase I INLIGHT trial, leading to a significant stock price increase. Group 1: Trial Results - The Phase I INLIGHT trial data for WVE-007 was released on December 8, showing a 9.4% reduction in visceral fat and a 4.5% decrease in total body fat after 12 weeks in 32 subjects receiving a single 240mg subcutaneous injection [1] - The trial participants, with a BMI of 28-35 kg/m², experienced an increase in lean body mass by 3.2% (approximately 4 pounds) [1] - The overall weight loss was only 0.9% due to muscle gain offsetting fat loss [1] Group 2: Efficacy and Administration - Serum Activin E levels reached a maximum suppression of 78% at 43 days, with efficacy maintained for over 85 days [1] - The results support the potential for administering the drug once or twice a year [1]